Bal Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Bal Pharma Ltd reported a 4.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.1%.
• Its expenses for the quarter were down by 6.5% QoQ and up 0.3% YoY.
• The net profit increased 101.1% QoQ and decreased 33.5% YoY.
• The earnings per share (EPS) of Bal Pharma Ltd stood at 2.26 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bal Pharma Ltd is a pharmaceutical company involved in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates primarily in the pharmaceutical industry, delivering healthcare solutions through its range of products that cater to various therapeutic categories. As of the latest data, there are no specific recent major developments available for Bal Pharma Ltd, nor any additional details regarding its strategic initiatives or market expansions.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Bal Pharma Ltd reported a total income of ₹83.84 crores, representing a slight year-over-year (YoY) increase of 1.1% from ₹82.96 crores in Q4FY25. However, there was a quarter-over-quarter (QoQ) decline of 4.7% compared to ₹88.02 crores in Q3FY26. This data suggests stability in the company's revenue generation on an annual basis, despite experiencing a contraction over the previous quarter. The revenue figures reflect the company's ability to maintain consistent sales performance over the year.

Profitability

The company's profit before tax for Q4FY26 stood at ₹3.22 crores, marking a substantial QoQ increase of 79.9% from ₹1.79 crores in Q3FY26 and a YoY growth of 24.3% over ₹2.59 crores in Q4FY25. The tax component for Q4FY26 was recorded at ₹-0.39 crores, which is notably different from the nil tax in Q3FY26 and ₹-2.83 crores in Q4FY25, highlighting a significant YoY tax variance of -86.2%. The profit after tax for Q4FY26 was ₹3.60 crores, which increased by 101.1% QoQ from ₹1.79 crores in Q3FY26, but decreased by 33.5% YoY from ₹5.41 crores in Q4FY25. Earnings per Share (EPS) mirrored this trend, rising QoQ by 101.8% to ₹2.26 from ₹1.12 in Q3FY26, while decreasing YoY by 33.5% from ₹3.40 in Q4FY25.

Operating Metrics

Total expenses for Q4FY26 were reported at ₹80.63 crores, indicating a minor YoY increase of 0.3% from ₹80.37 crores in Q4FY25, yet a QoQ decrease of 6.5% from ₹86.22 crores in Q3FY26. The reduction in expenses QoQ suggests an effective cost management strategy during the quarter. The significant rise in profit before tax and after tax on a QoQ basis, despite the decrease in total income, combined with reduced expenses, portrays a period of efficient financial operations for Bal Pharma Ltd. However, the YoY decrease in profit after tax and EPS indicates variability in profitability over the year.